Roche will discontinue development of RG1507, a monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R). The decision was due to the available clinical data, the large number of molecules targeting the same pathway that are presently in development and the prioritization of the Roche portfolio. The decision was not as a result of safety concerns. RG1507 is a fully human antibody created by Genmab under a collaboration with Roche. RG1507 was in Phase II developm...